Antonio Hardan, MD
Child & Adolescent Psychiatry · Palo Alto, CANPI 1407829286
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,458 of the $3,675 with a category attached, or 94.1%. 4 manufacturers reported payments, led by Roche Products Limited at 50.8% of the total. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5 payments — averaging $734.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$2K
- F. Hoffmann-la Roche AG$2K
- AbbVie$124
- Genentech, Inc.$93
Across 15 payments — averaging $10,433 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$114K
- Hoffmann-la Roche Limited$34K
- Genentech, Inc.$8K
What the payments were for
- Consulting fees$3,45894%
- Food & beverage$2176%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 2 | $1,868 |
| F. Hoffmann-la Roche AG | 1 | $1,590 |
| AbbVie | 1 | $124 |
| Genentech, Inc. | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,868
- VRAYLAR$124
How this compares
$3,675 in reported general payments places this provider in the 90th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $27,684 |
| Guanfacine Hcl | 18 | $1,203 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $987 |
| Fluvoxamine Maleate | 26 | $932 |
| Risperidone | 41 | $606 |
| Olanzapine OdtOlanzapine | 12 | $494 |
| Clonazepam | 38 | $378 |
| Trazodone Hcl | 29 | $370 |
| Aripiprazole | 31 | $319 |
| Fluoxetine Hcl | 22 | $176 |
| Benztropine Mesylate | 14 | $152 |
| Topiramate | 26 | $105 |
| Escitalopram Oxalate | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Palo Alto
- Lawrence FungPalo Alto$6K
- Shivani ChmuraPalo Alto$2K
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.